Rheumatoid Arthritis

Patients who achieved early remission with upadacitinib or adalimumab following an inadequate response to methotrexate had less pain/fatigue and better physical quality of life.

Patients with the highest daily step count had a 45% lower risk of RA compared with patients in the lowest quarter (< 6818 daily steps).

The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.

A study presented at EULAR 2024 found tender joint count was linked to depression and illness perception but not anxiety.

Phase 2 data showed a significant reduction in RA disease activity at Week 12 with weekly abiprubart, compared with placebo.

Phase 3 data showed patients treated with SHR0302 4 mg or 8 mg had greater improvements in ACR20 response rates and other key secondary outcomes versus placebo.

Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.

A greater proportion of patients in the FIL 200 mg group achieved meaningful patient-reported response compared with placebo.

Some of the risk factors for RA-interstitial lung disease include male sex, older age, and smoking history, a study found.

An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.

A new study found an indirect effect of RA on frailty index through inflammatory cytokines.

An analysis of CDC WONDER data details disparities among the cardiovascular mortality rate for patients with rheumatoid arthritis in the US.

As the severity of rheumatoid arthritis disease activity increases, so does the prevalence of depression, a new study found.

Age, chronic comorbidities, and COVID-19 vaccination status in patients with IMIDs serve as risk factors for severe COVID-19 outcomes.

When the serum cotinine levels were below -2.756 ng/mL, each 1 ng/mL increase in log-2-transformed serum cotinine levels increased the RA risk by 16.3%.

A real-world study from Spain suggests baricitinib demonstrated favorable effectiveness, adherence, and safety in rheumatoid arthritis, but investigators caution more research is needed.

These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.

Patients in the moderate and high disease activity cohorts reported significantly reduced health state utility values and HRQoL scores compared with the reference cohort.

A new study highlights the importance of daily antioxidant intake for endometriosis-related RA.

Lasso demonstrated advantages in predicting clinical remission in patients with RA treated with TNF, with a specificity of 69.9% and sensitivity of 61.7%.

Demographic, psychosocial, and clinical factors—along with patient-provider relationships—all impact medication adherence and patient satisfaction with RA treatment.

Internal dysbiosis was present in 66% of patients at baseline and was more common among those with a disease duration of > 2 years.

Patients with RA reported worse outcomes for all PROMs compared with CSA or UA.

Patients receiving abatacept experienced smaller increases in mean IMT, max IMT, and plaque score compared with the csDMARD cohorts.

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.